# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K223187 B Applicant

Instrumentation Laboratory Co.

# C Proprietary and Established Names

HemosIL Liquid Anti-XaHemosIL Rivaroxaban CalibratorsHemosIL Rivaroxaban ControlsHemosIL Apixaban CalibratorsHemosIL Apixaban ControlsHemosIL Heparin CalibratorsHemosIL UF Heparin ControlsHemosIL LMW Heparin Controls

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>QLU</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7295 -Heparin And Direct OralFactor Xa Inhibitor DrugTest System</td><td rowspan=1 colspan=1>HE - Hematology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

Clearance of HemosIL Liquid Anti-Xa for Rivaroxaban measurement with HemosIL Rivaroxaban Calibrators.

# B Measurand:

Heparin, Apixaban, Rivaroxaban

# C Type of Test:

Anti-Factor Xa chromogenic assay

III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

HemosIL Liquid Anti-Xa is an automated chromogenic assay for in vitro diagnostic use by laboratory professionals in clinical laboratories. The assay provides quantitative results on $3 . 2 \%$ citrated human plasma for the following analytes based on the calibrators used:

When used with HemosIL Heparin Calibrators:

Quantitative determination of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) activity on the ACL TOP Family and ACL TOP Family 50 Series.

When used with HemosIL Apixaban Calibrators:

Quantitative determination of apixaban on the ACL TOP Family and ACL TOP Family 50 Series through measurement of Factor Xa activity, which is inversely proportional to the apixaban level. With HemosIL Apixaban Calibrators, the assay is intended to measure apixaban concentrations in patients on apixaban therapy in the following situations where measurement of apixaban levels could be useful to have as additional information:

- Patients at risk for major bleeding - Patients experiencing a bleeding episode

# When used with HemosIL Rivaroxaban Calibrators:

Quantitative determination of rivaroxaban on the ACL TOP Family and ACL TOP Family 50 Series through measurement of Factor Xa activity, which is inversely proportional to the rivaroxaban level. With HemosIL Rivaroxaban Calibrators, the assay is intended to measure rivaroxaban concentrations in patients on rivaroxaban therapy in the following situations where measurement of rivaroxaban levels could be useful to have as additional information:

- Patients at risk for major bleeding - Patients experiencing a bleeding episode

The assay is not a stand-alone test and the results should be used in conjunction with other clinical and laboratory findings.

For use in adult population. For prescription use only.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only For use in adult population only For in vitro diagnostic use only

# D Special Instrument Requirements:

ACL TOP Family (K160276): ACL TOP 300 CTS; ACL TOP 500 CTS; ACL TOP 700; ACL TOP 700 CTS; ACL TOP 700 LAS

ACL TOP Family 50 Series (K150877): ACL TOP 350 CTS; ACL TOP 550 CTS; ACL TOP 750; ACL TOP 750 CTS; ACL TOP 750 LAS

# IV Device/System Characteristics:

# A Device Description:

HemosIL Liquid Anti-Xa is a one stage chromogenic assay based on a synthetic chromogenic substrate and on Factor Xa inactivation. The assay provides quantitative heparin, apixaban, and rivaroxaban results on $3 . 2 \%$ citrated human plasma when used with HemosIL Heparin Calibrators, HemosIL Apixaban Calibrators and/or Rivaroxaban Calibrators.

The HemosIL Liquid Anti-Xa assay consists:

# 4mL Kit Vial Size

• Factor Xa reagent $5 \mathrm { ~ x ~ } 2 . 5 \mathrm { ~ m L }$ vial of a liquid preparation containing purified bovine Factor Xa, Tris-Buffer, EDTA, dextran sulfate, sodium chloride and bovine serum albumin • Chromogenic substrate $5 \mathrm { ~ x ~ } 3 \mathrm { ~ m L }$ vial of liquid chromogenic substrate S-2732 and bulking agent

# 10mL Kit Vial Size

• Factor Xa reagent $5 \mathrm { ~ x ~ } 5 \mathrm { ~ m L }$ vial of a liquid preparation containing purified bovine Factor Xa, Tris-Buffer, EDTA, dextran sulfate, sodium chloride and bovine serum albumin • Chromogenic substrate $5 \mathrm { ~ x ~ } 6 \mathrm { ~ m L }$ vial of liquid chromogenic substrate S-2732 and bulking agent

The assay requires the following components which are not included in the assay kit:

HemosIL Rivaroxaban Calibrators- two levels (0 and $5 0 0 ~ \mathrm { { n g / m L } }$ ) of lyophilized calibrators prepared from human citrated plasma containing rivaroxaban, buffers, and stabilizers. HemosIL Rivaroxaban Controls- two levels (80 and $3 0 0 ~ \mathrm { { n g / m L } }$ ) of lyophilized controls prepared from human citrated plasma containing rivaroxaban, buffers, and stabilizers. HemosIL Apixaban Calibrators and Controls refer to DEN190032.   
HemosIL Heparin Calibrator and Controls (LMWH and UFH) refer to K090209.   
Cleaning solution   
Cleaning agent   
Factor diluent

# B Principle of Operation:

The HemosIL Liquid Anti-Xa is an anti-factor Xa one-stage chromogenic assay. When an excess amount of factor Xa is added to a sample containing rivaroxaban, factor Xa is partially

neutralized by rivaroxaban. Residual factor Xa is quantified when the synthetic chromogenic substrate is added to the patient sample. The released paranitroaniline (pNA) is released and monitored kinetically at $4 0 5 \mathrm { n m }$ . The measured pNA is inversely proportional to rivaroxaban levels. Thus, maximum absorption occurs with low levels of drug, and minimum absorption occurs with high levels of drug.

# V Substantial Equivalence Information:

A Predicate Device Name(s): HemosIL Liquid Anti-Xa

B Predicate 510(k) Number(s): DEN190032, K213464

C Comparison with Predicate(s):   

<table><tr><td colspan="3" rowspan="1">Comparison with Predicate(s):</td></tr><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K223187</td><td colspan="1" rowspan="1">K213464</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">HemosIL Liquid Anti-Xa</td><td colspan="1" rowspan="1">HemosIL Liquid Anti-Xa</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">HemosIL Liquid Anti-Xa is anautomated chromogenic assay for invitro diagnostic use by laboratoryprofessionals in clinical laboratories.The assay provides quantitativeresults on 3.2% citrated humanplasma for the following analytesbased on the calibrators used:When used with HemosILHeparin Calibrators:Quantitative determination ofunfractionated heparin (UFH) andlow molecular weight heparin(LMWH) activity on the ACL TOPFamily and ACL TOP Family 50Series.When used with HemosILApixaban Calibrators:Quantitative determination ofapixaban on the ACL TOP Familyand ACL TOP Family 50 Seriesthrough measurement of Factor Xaactivity, which is inverselyproportional to the apixaban level.With HemosIL Apixaban Calibrators,the assay is intended to measureapixaban concentrations in patientson apixaban therapy in the followingsituations where measurement ofapixaban levels could be useful tohave as additional information:- Patients at risk for major bleeding</td><td colspan="1" rowspan="1">HemosIL Liquid Anti-Xa is anautomated chromogenic assay for invitro diagnostic use by laboratoryprofessionals in clinical laboratories.The assay provides quantitativeresults on 3.2% citrated humanplasma for the following analytesbased on the calibrators used:• When used with HemosILHeparin Calibrators:Quantitative determination ofunfractionated heparin (UFH) andlow molecular weight heparin(LMWH) activity on the ACL TOPFamily, ACL TOP Family 50 Series.When used with HemosILApixaban Calibrators:Quantitative determination ofapixaban on the ACL TOP Familyand ACL TOP Family 50 Seriesthrough measurement of Factor Xaactivity, which is inverselyproportional to the apixaban level.With HemosIL ApixabanCalibrators, the assay is intended tomeasure apixaban concentrations inpatients on apixaban therapy in thefollowing situations wheremeasurement of apixaban levelscould be useful to have as additionalinformation:</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">- Patients experiencing a bleedingepisodeWhen used with HemosILRivaroxaban Calibrators:Quantitative determination ofrivaroxaban on the ACL TOP Familyand ACL TOP Family 50 Seriesthrough measurement of Factor Xaactivity, which is inverselyproportional to the rivaroxaban level.With HemosIL RivaroxabanCalibrators, the assay is intended tomeasure rivaroxaban concentrationsin patients on rivaroxaban therapy inthe following situations wheremeasurement of rivaroxaban levelscould be useful to have as additionalinformation:- Patients at risk for major bleeding- Patients experiencing a bleedingepisodeThe assay is not a stand-alone testand the results should be used inconjunction with other clinical andlaboratory findings.For use in adult population. Forprescription use only.*Note: Same as predicate except foraddition of Rivaroxaban.</td><td colspan="1" rowspan="1">- Patients experiencing a bleedingepisodeThe assay is not a stand-alone testand the results should be used inconjunction with other clinical andlaboratory findings.For use in adult population. Forprescription use only.</td></tr><tr><td colspan="1" rowspan="1">Technical Method/Test Methodology</td><td colspan="1" rowspan="1">One stage chromogenic assay basedon a synthetic chromogenic substrateand on factor Xa inactivation. Thetest detects residual factor Xa using achromogenic substrate. The signal oroptical density is compared to a drug-specific calibration curve and resultsare reported as nanograms permilliliter (ng/mL).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">3.2% citrated plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">The HemosIL Anti-Xa includes thefollowing components:Factor Xa reagent: Liquidpreparation containing purifiedbovine Factor Xa (approximately5.5 nkat/mL), Tris-Buffer, EDTA,dextran sulfate, sodium chlorideand bovine serum albumin.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">•  Chromogenic substrate: liquidchromogenic substrate S-2732(approximately 1.2 mg/mL) andbulking agent.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">ACL TOP Family (K160276)ACL TOP 50 Series (K150877)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Quality Control</td><td colspan="1" rowspan="1">Automated QC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Open ReagentStability</td><td colspan="1" rowspan="1">1 month</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On-board Stability</td><td colspan="1" rowspan="1">4 Days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">HeparinApixabanRivaroxaban</td><td colspan="1" rowspan="1">HeparinApixaban</td></tr><tr><td colspan="1" rowspan="1">Assay Volume</td><td colspan="1" rowspan="1">4 mL Vial SizeFactor Xa reagent 5 x 2.5 mLChromogenic substrate 5 x 3 mL10 mL Kit Vial SizeFactor Xa reagent 5 x 5 mLChromogenic substrate 5 x 6 mL</td><td colspan="1" rowspan="1">4 mL Vial SizeFactor Xa reagent 5 x 2.5 mLChromogenic substrate 5 x 3 mL</td></tr><tr><td colspan="1" rowspan="1">Limit of Detection</td><td colspan="1" rowspan="1">8 ng/mL for Rivaroxaban</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">20 ng/mL to 1000 ng/mLfor Rivaroxaban</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Calibrators(Sold Separately)</td><td colspan="1" rowspan="1">HemosIL Heparin Calibrators andHemosIL Apixaban Calibrators,HemosIL Rivaroxaban Calibrators;Target Levels: 0 and 500 ng/mL</td><td colspan="1" rowspan="1">HemosIL Heparin Calibrators;Targe levels: 0, 0.8 and 2.0 IU/mLHemosIL Apixaban Calibrators;Target Levels: 0 and 500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Controls(Sold Separately)</td><td colspan="1" rowspan="1">HemosIL Heparin Controls andHemosIL Apixaban Controls,HemosIL Rivaroxaban Controls;Target Levels: 80 and 300 ng/mL</td><td colspan="1" rowspan="1">HemosIL Heparin (LMW and UF)Controls; Target Levels: low andhighHemosIL Apixaban Controls;Target Levels: 75 and 300 ng/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

EP05-A3. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline−Third Edition, October 2014 (R2019).

EP06-A2. Evaluation of Linearity of Quantitative Measurement Procedure-Second Edition, April 2003.

EP07-Ed. 3. Interference Testing in Clinical Chemistry-Third Edition, November 2005 (R2022).

EP17-A2. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures;   
Approved Guideline−Second Edition, October 2004 (R2017).

EP34-Ed. 1. Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking-First Edition, August 2018.

EP37-Ed. 1. Supplement Tables for Interference Testing in Clinical Chemistry-First Edition, April 2018.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

Analytical performance studies for apixaban, low-molecular weight heparin (LMWH) and unfractionated heparin (UFH) were previously reported in DEN190032 (apixaban) and K090209 (LMWH, UFH), respectively.

# 1. Precision/Reproducibility:

Four precision studies were performed following the recommendations of the CLSI EP05-A3 guideline.

Study 1: This study was conducted over 20 days, two runs per day and two replicates per run for a total of 480 determinations (i.e., 80 determinations per reagent lot). The study design included three representative ACL TOP Family instrument models, two reagent lots (each lot was tested on all instrument models), as well as three spiked plasma samples and one patient pool. Precision estimates were calculated for each of the following variance component: within-run, between-run, between-day, between-lot and within laboratory. The results are provided in the summary table below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>RivaroxabanMean ng/mL</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>50.2</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.15</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.32</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>787.2</td><td rowspan=1 colspan=1>11.25</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>12.00</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>6.18</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>6.70</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>23.71</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Spiked 3</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>928.2</td><td rowspan=1 colspan=1>11.91</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>17.18</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>17.55</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>33.77</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>PlasmaPool</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>127.2</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.04</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.04</td><td rowspan=1 colspan=1>2.4</td></tr></table>

Study 2: This study was conducted over 20 days, two runs per day and two replicates per run for a total of 720 determinations (i.e., 80 determinations per reagent lot). The study design included three representative ACL TOP Family 50 Series instrument models, three reagent lots (each lot was tested on all instrument models), as well as three spiked plasma samples and one patient pool. Precision estimates were calculated for each of the following variance component: within-run, between-run, between-day, between-lot and within laboratory. The results are provided in the summary table below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>RivaroxabanMean ng/mL</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>50.7</td><td rowspan=1 colspan=1>2.10</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>777.2</td><td rowspan=1 colspan=1>19.90</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>6.28</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>11.03</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>38.80</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>Spiked 3</td><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>923.4</td><td rowspan=1 colspan=1>17.40</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.44</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>10.32</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.52</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>40.36</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>PlasmaPool</td><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>127.9</td><td rowspan=1 colspan=1>2.44</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>5.19</td><td rowspan=1 colspan=1>4.1</td></tr></table>

Study 3: This study was conducted over 20 days, two runs per day and two replicates per run for a total of 480 determinations (i.e., 80 determinations per reagent lot). The study design included two representative ACL TOP Family and ACL TOP Family 50 Series instrument models, three reagent lots (each lot was tested on all instrument models), native MDL trough and peak rivaroxaban plasma samples. Precision estimates were calculated for each of the following variance component: within-run, between-run, between-day, between-lot and within laboratory. The results are provided in the summary table below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>RivaroxabanMean ng/mL</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Native 5(Trough)</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>32.4</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.70</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Native 6(Peak)</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>428.0</td><td rowspan=1 colspan=1>6.32</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>5.54</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>11.06</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Study 4: This study was conducted at three sites by three operators (1 operator per site), over 5 days, two runs per day and three replicates per run for a total of 270 determinations (i.e., 30 determinations per reagent level). The study design included three different ACL TOP Family instruments, three reagent lots (i.e., one per instrument and the same reagent lots were used across all sites), as well as two quality controls, three spiked plasma samples and two patient pools. Precision estimates were calculated for each of the following variance component: within-run, between-run, between-day, between-site, between-lot, and reproducibility. The results are provided in the summary table below.

<table><tr><td rowspan=1 colspan=15>Pooled 3 Site Data</td></tr><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>Mean(ng/mL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Reproducibility(Total)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LowControl</td><td rowspan=1 colspan=1>72.6</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>2.28</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>3.00</td><td rowspan=1 colspan=1>4.1%</td></tr><tr><td rowspan=1 colspan=1>HighControl</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>4.58</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>4.10</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>6.51</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=1 colspan=1>Spiked 1</td><td rowspan=1 colspan=1>45.0</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>4.41</td><td rowspan=1 colspan=1>9.8%</td></tr><tr><td rowspan=1 colspan=1>Spiked 2</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>19.68</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>6.30</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>22.12</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>5.26</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>30.76</td><td rowspan=1 colspan=1>4.1%</td></tr><tr><td rowspan=1 colspan=1>Spiked 3</td><td rowspan=1 colspan=1>939</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>25.49</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>3.43</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>7.41</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>22.98</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>8.83</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>36.36</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>PlasmaPool 1</td><td rowspan=1 colspan=1>51.8</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>3.39</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaPool 2</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>3.71</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>4.29</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>2.76</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>5.71</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>8.67</td><td rowspan=1 colspan=1>7.3%</td></tr></table>

Linearity studies were performed following the CLSI EP06-A2 guideline using three different reagent lots tested on a representative ACL TOP Family and an ACL TOP Family 50 series model. Normal Pooled Plasma spiked with known concentrations of rivaroxaban was tested in four replicates. Two separate linear regressions were performed. For the first, samples with thirteen different concentrations were evaluated to establish the analytical measuring interval; and for the second, samples with nine different concentrations were evaluated to establish the extended measuring interval.

Based on the results of the Linearity studies and Detection Limit studies, the claimed assay reportable range is $2 0 { - } 1 0 0 0 ~ \mathrm { n g / m L }$ .

# 3. Analytical Specificity/Interference:

Interference studies were conducted based on the CLSI EP07-A2 guideline and CLSI EP37 guideline. The study design included one representative instrument model and one regent lot. Potentially interfering endogenous and exogenous substances were spiked into the test samples (rivaroxaban at $5 0 ~ \mathrm { n g / m L }$ , $1 8 0 ~ \mathrm { n g / m L }$ or $4 0 0 ~ \mathrm { { n g / m L } }$ native donor samples collected at peak and trough), and each sample level were run in five replicates on an ACL TOP family instrument.

Rivaroxaban results on ACL TOP Family and ACL TOP Family 50 Series are not affected by the interferents listed up to the concentrations detailed in the table below.

<table><tr><td rowspan=1 colspan=1>Interfering Substances</td><td rowspan=1 colspan=1>Concentration without Interference</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>921 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lupus anticoagulant</td><td rowspan=1 colspan=1>dRVVT Screen/Confirm Ratio 2.47(dRVVT: Diluted Russell Viper Venom Time)</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>3.00 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Atorvastatin</td><td rowspan=1 colspan=1>0.075 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Isosorbide dinitrate</td><td rowspan=1 colspan=1>0.600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ticagrelor</td><td rowspan=1 colspan=1>0.188 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Warfarin</td><td rowspan=1 colspan=1>7.50 mg/dL</td></tr></table>

Rivaroxaban results may be falsely elevated in samples tested post-andexanet alfa administration.

The assay is not intended for the monitoring and dosage adjustment of rivaroxaban.

Administer a reversal agent based on current clinical guidance, and take into consideration other clinical and laboratory findings including the Factor Xa inhibitor dose and time since last dose. For additional information, refer to current clinical guidance and reversal agent prescribing information.

# 4. Assay Reportable Range:

HemosIL Liquid Anti-Xa Assay Reportable Range: $2 0 { \mathrm { - } } 1 0 0 0 \ \mathrm { n g / m L }$ rivaroxaban.

# Traceability

Calibrator value assignments are traceable to Rivaroxaban supplied by the manufacturer and quantitated in plasmas assayed by liquid chromatography-tandem mass spectrometry (LCMS/MS). Two levels of lyophilized calibrators prepared from human citrated plasma by means of a dedicated process at two different concentrations containing rivaroxaban, buffers, and stabilizers. A house standard lot of HemosIL Rivaroxaban Calibrators is used to value assign each new lot of Rivaroxaban Calibrator 2.

Expected values: Calibrator 1 $\therefore 0 \mathrm { n g / m L }$ Calibrator $2 \colon 5 0 0 ~ \mathrm { n g / m L }$

HemosIL Liquid Anti-Xa assay uses Rivaroxaban Controls when calibrated with HemosIL Rivaroxaban Calibrators. Two levels of lyophilized HemosIL Rivaroxaban controls are prepared from human citrated plasma by means of a dedicated process at two different concentrations containing rivaroxaban, buffers, and stabilizers.

Expected values: Low Control : $8 0 ~ \mathrm { n g / m L }$ High Control : $3 0 0 ~ \mathrm { { n g / m L } }$

# Sample Stability

Sample stability studies were performed to support the recommended storage and handling instructions detailed in device labeling. Citrated plasma samples were tested after storage in the following temperature ranges $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ and $2 { - } 8 ^ { \circ } \mathrm { C }$ . The study was performed using one reagent lot with three contrived samples and two native (trough and peak) samples. The contrived samples were tested in quadruplicate and native samples were tested in 8 replicates for baseline then in quadruplicate for various time intervals. The study demonstrated specimens are stable up to 24 hours at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ and up to 7 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

# Reagent Stability

The results support the following claim: Open Vial $2 { - } 8 ^ { \circ } \mathrm { C }$ for 1 month, On-Board Instrument $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ for 4 days, Shelf-life $2 { - } 8 ^ { \circ } \mathrm { C }$ for 30 Months.

# 6. Detection Limit:

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) for the test system was determined following CLSI EP17-A2 guideline. Each study design included three reagent lots, an ACL TOP Family and ACL TOP Family 50 Series instruments.

The LoB was determined using four citrated plasma pools containing no rivaroxaban. Three replicate measurements were tested for each of the four plasma pools on five different days on two different instrument models for 60 determinations per reagent lot per instrument model. The LoB was determined to be $2 . 4 ~ \mathrm { n g / m L }$ .

The LoD was determined using four citrated plasma pools containing low levels of rivaroxaban around $1 0 ~ \mathrm { n g / m L }$ . Three replicate measurements were tested for each of the four plasma pools on five different days on two different instrument models for 60 determinations per reagent lot per instrument model. The LoD was determined to be $8 ~ \mathrm { n g / m L }$ .

The LoQ was determined using four citrated plasma pools spiked with four target concentration 15, 20, 30, $5 0 ~ \mathrm { n g / m L }$ of rivaroxaban. Eight replicate measurements were tested for each of the four plasma pools on five different days on two different instrument models for 40 determinations per reagent lot per instrument model. The LoQ was determined to be $2 0 ~ \mathrm { n g / m L }$ .

7. Assay Cut-Off:

Not Applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

The method comparison study was conducted using the HemosIL Liquid Anti-Xa assay on three ACL TOP Family instrument models by testing 337 clinical samples collected from patients receiving rivaroxaban at three different US clinical sites. Results from the HemosIL Liquid Anti-Xa were compared to results from a validated rivaroxaban liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Weighted Deming regression analysis was performed for the dataset collected and the result is shown in the following table.

<table><tr><td rowspan=1 colspan=1>SampleNumber</td><td rowspan=1 colspan=1>RivaroxabanRange(ng/mL)</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td></tr><tr><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>20.3940.4</td><td rowspan=1 colspan=1>0.995</td><td rowspan=1 colspan=1>0.971(0.953, 0.990)</td><td rowspan=1 colspan=1>-0.697(-3.087, 1.692)</td></tr></table>

2. Matrix Comparison: Not Applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not Applicable.

2. Clinical Specificity: Not Applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not Applicable.

D Clinical Cut-Off: Not Applicable.

# E Expected Values/Reference Range:

The HemosIL Liquid Anti-Xa assay is not intended to monitor patients on rivaroxaban therapy. Rivaroxaban does not require therapeutic monitoring, thus, there is no standard therapeutic range as the on-therapy range may be different for each individual patient.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.